China National Accord Medicines Corporation Ltd (Sinopharm Accord) is affiliated with China National Pharmaceutical Group Co Ltd (Sinopharm) and Sinopharm Group Co Ltd (Sinopharm Holding). It is a comprehensive pharmaceutical listed company with a complete industrial chain of “distribution + retail + industrial investment”. Sinopharm Accord has a nationwide pharmaceutical retail network and a distribution network that covers Guangdong province and the Guangxi Zhuang autonomous region. It maintains cooperation with the top 100 global pharmaceutical companies and healthcare product companies, providing professional healthcare services to hundreds of millions of people in China. Sinopharm Accord supplies pharmaceutical products to approximately 330,000 hospitals, retail pharmacies, pharmaceutical distributors and community health centers in Guangdong and Guangxi.
Sinopharm Accord achieved a business revenue of over 70 billion yuan ($9.82 billion) in 2021, ranking 50th in the Top 500 Enterprises in Guangdong province and 23rd among Shenzhen’s Top 100 Enterprises.
Against the background of the new health care reform, Sinopharm Accord has rapidly transformed itself by innovating its intelligent supply chain and service principles and strengthening cooperation between wholesale and retail channels. It has developed new types of business, including retail clinics, direct retail sales and medical equipment and consumable sales, and has explored diversified and collaborative development models. It has also established a prescription medicine retail brand called “Sinopharm Holding Pharmacy” to build a platform for medical equipment supply chain integration.
Sinopharm Accord is transforming into an excellent health care product and service provider that defines industry standards. It has cooperated with Walgreens Boots Alliance Inc - a strategic investor and the world's first pharmaceutical and healthcare enterprise to focus on pharmacies - to leverage the value of its nationwide network of over 10,000 terminal stores, and to build a trusted Chinese pharmaceutical and healthcare retail brand for consumers. With its large scale, Sinopharm Accord aims to become a high-quality pharmaceutical and healthcare product and service provider, an easily accessible brand to consumers and a platform integrating wholesale and retail businesses.
China National Accord Medicines Corporation Ltd (Sinopharm Accord) is affiliated with China National Pharmaceutical Group Co Ltd (Sinopharm) and Sinopharm Group Co Ltd (Sinopharm Holding). It is a comprehensive pharmaceutical listed company with a complete industrial chain of “distribution + retail + industrial investment”. Sinopharm Accord has a nationwide pharmaceutical retail network and a distribution network that covers Guangdong province and the Guangxi Zhuang autonomous region. It maintains cooperation with the top 100 global pharmaceutical companies and healthcare product companies, providing professional healthcare services to hundreds of millions of people in China. Sinopharm Accord supplies pharmaceutical products to approximately 330,000 hospitals, retail pharmacies, pharmaceutical distributors and community health centers in Guangdong and Guangxi.
Sinopharm Accord achieved a business revenue of over 70 billion yuan ($9.82 billion) in 2021, ranking 50th in the Top 500 Enterprises in Guangdong province and 23rd among Shenzhen’s Top 100 Enterprises.
Against the background of the new health care reform, Sinopharm Accord has rapidly transformed itself by innovating its intelligent supply chain and service principles and strengthening cooperation between wholesale and retail channels. It has developed new types of business, including retail clinics, direct retail sales and medical equipment and consumable sales, and has explored diversified and collaborative development models. It has also established a prescription medicine retail brand called “Sinopharm Holding Pharmacy” to build a platform for medical equipment supply chain integration.
Sinopharm Accord is transforming into an excellent health care product and service provider that defines industry standards. It has cooperated with Walgreens Boots Alliance Inc - a strategic investor and the world's first pharmaceutical and healthcare enterprise to focus on pharmacies - to leverage the value of its nationwide network of over 10,000 terminal stores, and to build a trusted Chinese pharmaceutical and healthcare retail brand for consumers. With its large scale, Sinopharm Accord aims to become a high-quality pharmaceutical and healthcare product and service provider, an easily accessible brand to consumers and a platform integrating wholesale and retail businesses.